Elephas Biosciences Corporation and Invitrocue Pte. Ltd, have partnered to expand personalized oncology in Southeast Asia, the company announced recently.

Invitrocue will serve as Elephas’ commercial partner for the elive platform in Singapore and Malaysia.

“Our partnership with Invitrocue represents an important step in expanding access to the elive platform through a recognized leader in personalized oncology,” Elephas Founder and CEO Maneesh Arora said in a statement. “Through this partnership, we have an opportunity to provide researchers and clinicians with functional insights while broadening personalized cancer care throughout Southeast Asia.”

According to a release, the partnership brings together three complementary approaches: Invitrocue’s Onco-PDO® functional drug testing service, its suite of CGP tests and Elephas’ elive platform for ex vivo immunotherapy response insight.